Industry Orgs Urge FDA to Delay New Quality Metrics Program

Drug GMP Report
A A
A broad group of industry organizations is urging the FDA to delay its quality metrics reporting program, which would require drugmakers to aggregate information on the number of lots started, released for distribution and found out-of-specification, as well as the number of quality complaints reported.

To View This Article:

Login

Subscribe To Drug GMP Report